尿液中嗅质蛋白4预测危重患儿呋塞米反应及肾脏替代治疗
该前瞻性观察性队列研究纳入两家四级监护PICU的240例肾绞痛指数≥8且入住PICU第0-1天留取尿样的患儿,其中56例在PICU第1-4天接受呋塞米剂量,44例接受KRT。研究发现呋塞米无反应组uOLFM4和uNGAL中位浓度均显著高于反应组,接受KRT者浓度也更高。uOLFM4与uNGAL预测呋塞米反应的AUC分别为0.77(95%CI 0.65-0.90)和0.71(95%CI 0.57-0.85),uOLFM4阈值156 ng/mL预测呋塞米反应的敏感度59%、特异度96%、阳性预测值64%、阴性预测值95%。作者认为uOLFM4对两种结局的阴性预测值≥95%,使其成为有前景的临床决策支持候选指标,以促进早期KRT启动决策。
要点
- 在肾绞痛指数≥8的PICU患儿中,呋塞米无反应者uOLFM4中位浓度694 ng/mL(IQR 214-1478)显著高于反应者139 ng/mL(IQR 46-529),p=0.0004。
- uOLFM4预测呋塞米反应的AUC为0.77(95%CI 0.65-0.90,p=0.0005),uNGAL为0.71(95%CI 0.57-0.85,p=0.0088),两者判别能力中等且相似。
- uOLFM4阈值156 ng/mL预测呋塞米反应的敏感度59%、特异度96%、阳性预测值64%、阴性预测值95%。
- 呋塞米无反应组uNGAL中位浓度1149 ng/mL(IQR 204-2284)显著高于反应组53 ng/mL(IQR 50-1533),p=0.0076。
- uOLFM4和uNGAL在PICU第1天对呋塞米反应及KRT启动均具有中等判别能力,uOLFM4对两种结局的阴性预测值≥95%。
适用人群与场景
- 两家四级监护PICU的240例患儿,肾绞痛指数≥8,且在PICU第0-1天留取尿样。
- 其中56例在PICU第1-4天接受呋塞米剂量,44例接受KRT。
诊断标准与关键阈值
- 肾绞痛指数≥8定义为急性肾损伤高危。
- uOLFM4阈值156 ng/mL用于预测呋塞米反应,敏感度59%、特异度96%、阳性预测值64%、阴性预测值95%。
研究设计与关键结果
- 研究类型:前瞻性观察性队列研究;样本量240例;两家四级监护PICU;人群为肾绞痛指数≥8的PICU患儿。
- 干预:无;uOLFM4通过酶联免疫吸附测定法测量,uNGAL通过颗粒增强透射免疫比浊法由临床实验室测量。
- 主要终点:呋塞米无反应组uOLFM4中位浓度694 ng/mL(IQR 214-1478)vs 反应组139 ng/mL(IQR 46-529),p=0.0004;uNGAL无反应组1149 ng/mL(IQR 204-2284)vs 反应组53 ng/mL(IQR 50-1533),p=0.0076。
- uOLFM4和uNGAL预测呋塞米反应的AUC分别为0.77(95%CI 0.65-0.90;p=0.0005)和0.71(95%CI 0.57-0.85;p=0.0088)。
- uOLFM4和uNGAL浓度在接受KRT的患者中更高。
- uOLFM4阈值156 ng/mL预测呋塞米反应:敏感度59%、特异度96%、阳性预测值64%、阴性预测值95%。
证据类型、等级与局限
- 证据类型:前瞻性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在急性肾损伤高危危重患儿中,uOLFM4和uNGAL可能有助于在PICU第1天预测呋塞米反应和KRT启动,uOLFM4对两种结局的阴性预测值≥95%,作者认为其有前景纳入临床决策支持以促进早期KRT启动决策。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To test whether urine olfactomedin 4 (uOLFM4) can predict furosemide responsiveness in patients at high risk for acute kidney injury (AKI) early in the PICU course. A secondary outcome was prediction of kidney replacement therapy (KRT) initiation in this cohort.
DESIGN: Prospective observational cohort study.
SETTING: Two quaternary care PICUs.
PATIENTS: Two hundred forty PICU patients with a renal angina index greater than or equal to 8 and a urine sample collected on PICU days 0-1. Fifty-six patients received a furosemide dose on PICU days 1-4 and 44 received KRT.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: uOLFM4 was measured via enzyme-linked immunosorbent assay. Urine neutrophil gelatinase-associated lipocalin (uNGAL) was measured via particle-enhanced turbidimetric immunoassay by the clinical laboratory. We compared groups using Mann-Whitney U tests or Kruskal-Wallis tests and calculated area under the receiver operating characteristic curve for performance of uOLFM4 and uNGAL to predict furosemide responsiveness on PICU days 1-4 and KRT receipt. Median (interquartile range) uOLFM4 and uNGAL concentrations were higher in patients who were furosemide nonresponsive (uOLFM4 694 ng/mL [214-1478 ng/mL] vs. 139 ng/mL [46-529 ng/mL]; p = 0.0004 and uNGAL 1149 ng/mL [204-2284 ng/mL] vs. 53 ng/mL [50-1533 ng/mL]; p = 0.0076) and higher in patients who received KRT. uOLFM4 and uNGAL had similar moderate discriminatory ability to predict furosemide responsiveness (area under the curve, 0.77 [95% CI, 0.65-0.90]; p = 0.0005 and 0.71 [95% CI, 0.57-0.85]; p = 0.0088, respectively). uOLFM4 of 156 ng/mL had 59% sensitivity, 96% specificity, a positive predictive value of 64%, and negative predictive value (NPV) of 95% to predict furosemide responsiveness.
CONCLUSIONS: In critically ill children at high risk for AKI, both uOLFM4 and uNGAL have moderate discriminatory ability to predict furosemide responsiveness and KRT receipt on the first day of PICU stay. The NPV greater than or equal to 95% for uOLFM4 for both outcomes make it a promising candidate for implementation into clinical decision support to facilitate early KRT initiation decision-making.
参考来源
- Hasson DC, Clover-Brown I, Zepeda-Orozco D, et al. Urine Olfactomedin 4 Predicts Furosemide Response and Kidney Replacement Therapy in Critically Ill Children. Crit Care Explor. 2025. PMID: 41334875. doi:10.1097/CCE.0000000000001356
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。